Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Table 1

Clinical trials with anti-EGFR monoclonal antibodies in postprogression treatment.

Study	No. of patients	Design	Treatment	Primary end point	Results
BOND [19]	329	Phase 3, open-label, RCT	C-mab versus C-mab + irinotecan	ORR	10.8% versus 22.9%	0.007
CO17 [20]	572	Phase 3, RCT	BSC versus C-mab	OS	HR, 0.77; 95% CI, 0.64–0.92	0.005
EPIC [21]	1298	Phase 3, open-label, RCT	Irinotecan versus C-mab + irinotecan	OS	HR, 0.975; 95% CI, 0.85–1.11	0.71
Van Cutsem et al. [22]	463	Phase III, open-label, RCT	BSC versus P-mab + BSC	PFS	HR, 0.54; 95% CI, 0.44–0.66	<0.0001
Peeters et al. [23]	1186	Phase III, open-label, RCT	FOLFIRI versus P-mab + FOLFIRI	PFS	HR, 0.73; 95% CI, 0.59–0.9	0.004
				OS	HR, 0.85; 95% CI, 0.7–1.04	0.12
PICCOLO [26]	460	Phase III, open-label, RCT	Irinotecan versus P-mab + irinotecan	OS	HR, 1.01; 95% CI, 0.83–1.23	0.91

EGFR: epidermal growth factor receptor; No.: number; RCT: randomized controlled trial; pt: patient; C-mab: cetuximab; ORR: objective response rate; BSC: best supportive care; OS: overall survival; HR: hazard ratio; P-mab: panitumumab; PFS: progression-free survival.